Figures & data
Figure 1 Patients with a COPD diagnosis without a concomitant asthma diagnosis in the Swedish National Airway Register (SNAR) registered by primary care and lung specialists between June 1, 2018 and November 30, 2019. In total 15,595 patients were classified according to the GOLD A-D classification system and included in the analyses.
![Figure 1 Patients with a COPD diagnosis without a concomitant asthma diagnosis in the Swedish National Airway Register (SNAR) registered by primary care and lung specialists between June 1, 2018 and November 30, 2019. In total 15,595 patients were classified according to the GOLD A-D classification system and included in the analyses.](/cms/asset/7ccefe39-ce0e-4155-8df9-9f7ea109c648/dcop_a_12163832_f0001_b.jpg)
Table 1 Patient Characteristics
Table 2 Outcomes in 10,539 COPD Patients in Whom Both CAT Scores and mMRC Scores Were Available
Table 3 Treatment of 15,595 COPD Patients According to the GOLD A-B-C-D Classification
Figure 2 Proportion of patients in GOLD groups A, B, C and D who were prescribed no pharmacological treatment, short-acting bronchodilators (SABD) only, any long-acting bronchodilator without an inhaled steroids (any LA without ICS) and inhaled steroids alone or in combination with bronchodilators (any ICS).
![Figure 2 Proportion of patients in GOLD groups A, B, C and D who were prescribed no pharmacological treatment, short-acting bronchodilators (SABD) only, any long-acting bronchodilator without an inhaled steroids (any LA without ICS) and inhaled steroids alone or in combination with bronchodilators (any ICS).](/cms/asset/719a90f2-859c-4c71-9261-074c57b02baa/dcop_a_12163832_f0002_b.jpg)
Table 4 Influence of Gender, Age, Lung Function, Symptoms (CAT) and Exacerbations History as Assessed by Multiple Logistic Regression in GOLD Group A and B Patients Stratified for Treatment with ICS. Any Steroids Implicate Treatment with an Inhaled Steroid Alone or in Any Combination with Other Inhaled Drugs